Summary of opinion: Stelara, 25/06/2026 Positive
Opinion
On 25 June 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Stelara. The marketing authorisation holder for this medicinal product is Janssen Cilag International.
The CHMP adopted a new indication as follows:
Paediatric ulcerative colitis
Stelara is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients from the age of 2 years and older, who have had an inadequate response to, or were intolerant to either conventional therapy or a biologic.
For information, the full indications for Stelara will now be:
Plaque psoriasis
Stelara is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate (MTX) or PUVA (psoralen and ultraviolet A) (see section 5.1).
Paediatric plaque psoriasis
Stelara is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies (see section 5.1).
Psoriatic arthritis (PsA)
Stelara, alone or in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease modifying anti rheumatic drug (DMARD) therapy has been inadequate (see section 5.1).
Adult Crohn’s disease
Stelara is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist.
Paediatric Crohn's disease
Stelara is indicated for the treatment of moderately to severely active Crohn’s disease in paediatric patients from the age of 2 years and older, who have had an inadequate response to, or were intolerant to either conventional or biologic therapy.
Ulcerative colitis
Stelara is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic.
Paediatric ulcerative colitis
Stelara is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients from the age of 2 years and older, who have had an inadequate response to, or were intolerant to either conventional therapy or a biologic.
Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.
Note**:** New text in bold
CHMP post-authorisation summary of positive opinion for Stelara (VR-0000316205)
Adopted
Reference Number:
EMADOC-1700519818-3138737
English (EN) (141.67 KB - PDF)
First published:
26/06/2026
View
Key facts
Name of medicine
Stelara
EMA product number
EMEA/H/C/000958
Active substance
ustekinumab
International non-proprietary name (INN) or common name
ustekinumab
Therapeutic area (MeSH)
- Psoriasis
- Arthritis, Psoriatic
- Crohn Disease
- Colitis, Ulcerative
Anatomical therapeutical chemical (ATC) code
L04AC05
Marketing authorisation holder
Janssen-Cilag International NV
Date of opinion
25/06/2026
Status
Positive
News on Stelara
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2026
26/06/2026
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 February 2026
27/02/2026
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 February 2025
28/02/2025
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 24 - 27 October 2022
28/10/2022
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2019
13/12/2019
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2019
26/07/2019
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2016 (corrected)
21/09/2016
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 May 2015
22/05/2015
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 January 2014
24/01/2014
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2013
26/07/2013
More information on Stelara
This page was last updated on
25/06/2026
Summary
On 25 June 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Stelara. The marketing authorisation holder for this medicinal product is Janssen Cilag International. The CHMP adopted a new indication as follows: Paediatric ulcerative colitis Stelara is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients from the age of 2 years and older, who have had an inadequate response to, or were intolerant to either conventional therapy or a biologic. For information, the full indications for Stelara will now be: Plaque psoriasis Stelara is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate (MTX) or PUVA (psoralen and ultraviolet A) (see section 5.1). Paediatric plaque psoriasis Stelara is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies (see section 5.1). Psoriatic arthritis (PsA) Stelara, alone or in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease modifying anti rheumatic drug (DMARD) therapy has been inadequate (see section 5.1). Adult Crohn's disease Stelara is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist. Paediatric Crohn's disease Stelara is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients from the age of 2 years and older, who have had an inadequate response to, or were intolerant to either conventional or biologic therapy. Ulcerative colitis Stelara is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic. Paediatric ulcerative colitis Stelara is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients from the age of 2 years and older, who have had an inadequate response to, or were intolerant to either conventional therapy or a biologic. Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission. Note: New text in bold